ZAG-a novel biomarker for cardiovascular risk in ESRD patients?
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 30348303.
- Also identified by DOI 10.1016/j.kint.2018.08.010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
End-stage renal disease (ESRD) is associated with an exceedingly high risk of cardiovascular disease. Traditional risk factors function differently in ESRD, which has prompted a search for novel mechanisms and biomarkers. In an observational study, Bouchara et al. identified zinc-alpha2-glycoprotein (ZAG) as a prognostic marker for cardiovascular events and mortality in patients on dialysis. Although the study raises important questions, the results should be interpreted cautiously and need to be confirmed in independent studies.
Medical subject headings
- Cardiovascular Diseases
- Kidney Failure, Chronic